InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 103540

Wednesday, 12/05/2012 2:55:00 PM

Wednesday, December 05, 2012 2:55:00 PM

Post# of 346050
Cotara - brain surgery much more advanced over past 5 years

.."Furthermore, dual modality imaging contrast was developed by conjugating 800CW-PGN635 to magnetic iron oxide nanoparticles"

Here an article about Peregrines Imaging program... notice the acknowledgement on the bottom: "Acknowledgments: We thank Peregrine Pharmaceuticals Inc., Tustin, CA, for the provision of PGN635 antibody. This work was supported in part by NCI 1R21 CA141348-01A1 and NIH CTSA Grant UL1 RR024982 and by the Meredith D. Chesler Foundation, Dallas, TX. Imaging was conducted by the Southwestern Small Animal Imaging Research Program (U24 CA126608), DOE grant #DE-FG02-05CH11280, and NIH BTRP # P41-RR02584."

http://www.wmicmeeting.org/2011/2011abstracts/data/papers/P663.html

-------------------------------------------------

Similar approach... using "nanoparticles"...

.."About 14,000 people are diagnosed annually with brain cancer in the United States. Of those cases, about 3,000 are glioblastomas, the most aggressive form of brain tumor. The prognosis for glioblastoma is bleak: the median survival time without treatment is three months."

http://med.stanford.edu/ism/2012/april/nanoparticle.html

------------------------------------------------

All and all... Peregrine is much further along at this point... now FDA approving their phase III and I consider this much more important since its just an added bonus to go along with the Bavi platform for our future partner

IMHO... I expect the pps to continue to trend up... after the games being played play themselves out of their short positions and reload on the long side
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News